Form D · Biotechnology
Ventus Therapeutics U.S., Inc.
Waltham, MA · CIK 0001794785
Offering snapshot reported Feb 11, 2022 · SEC filing
- Reported sold
- $70M Offering amount: $140M
- Investors reported
- 13 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Feb 7, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Feb 11, 2022 | Initial | $70,000,006 | No comparison | 13 | SEC filing |
| Apr 14, 2021 | Initial | $99,999,989 | No comparison | 17 | SEC filing |
| May 7, 2020 | Initial | $16,775,161 | No comparison | 4 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-433406
Source: Form D, filed Feb 11, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Marcelo Bigal | Director, Executive |
| Brendan Bulik Sullivan | Director |
| John Cassidy | Director |
| Michael Crackower | Executive |
| Jerel Davis | Director |
| Steven James | Director |
| Daniel Koerwer | Executive |
| Zachary Mc Nealy | Executive |
| Jane Pritchett Henderson | Director |
| Josh Resnick | Director |
| Dolca Thomas | Director |
| Markus Warmuth | Director |
| Hao Wu | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
100 Beaver Street, Suite 202
Waltham, MA, 02453
Waltham, MA, 02453